Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: A case report

Journal of Chemotherapy

Volumn 19, Issue 3, 2007, Pages 343-346

  Berretta, M ^a   Martellotta, F ^a   Simonelli, C ^a   Di Benedetto, F ^b   De Ruvo, N ^b   Drigo, A ^a   Bearz, A ^a   Spina, M ^a   Zanet, E ^a   Berretta, S ^c   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Folfiri; HAART; HIV

Indexed keywords

AMPRENAVIR PHOSPHATE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LAMIVUDINE; OXALIPLATIN; ZIDOVUDINE;

ADULT; ADVANCED CANCER; ANAMNESIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LABORATORY TEST; LOADING DRUG DOSE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; OPPORTUNISTIC INFECTION; PROTEIN EXPRESSION; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 34447513675     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.3.343     Document Type: Article

References (22)

1. Chong G, Cunningham D. The role of cetuximab in the therapy of previously treated advanced colorectal cancer. Sem Oncol 2005; 32 (6 suppl 9): S55-8.
2. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monothearpy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
3. Chung KY, Saltz LB. Antibody-Based Therapies for colorectal cancer. Oncologist 2005;10:701-9.
4. Herida M, Mary-Krause M, Kaplan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 15,21 (18):3447-53.
5. Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin N Am 2003; 17:889-99.
6. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. JCO 2006; 24:1383-8.
7. Berretta M, Martellotta F, Spina M, et al. Clinical features and outcome of colorectal cancer in HIV-infected people: a GICAT experience [Abstract]. Gastrointestinal Cancers Symposium - Am Soc Clin Oncol GI Meeting, 2005, Abstract # 201.
8. Berretta M, Di Benedetto F, Simonelli C, et al Multidisciplinary approach in a HIV/HCV-positive patient with liver metastases by colorectal cancer in the HAART-era. Ann Oncol. 2006; 17 (8): 1333-4.
9. Berretta M, Simonelli C, Lleshi A, et al. Oxaliplatin-based chemotherapy in association with highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients. Ann Oncol. 2006; 17(4):712-2.
10. Andrè T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. JCO 1999; 1: 3560-8.
11. Andrè T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35(9): 1343-7.
12. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993; 341: 441.
13. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44(2): 111-45.
14. WHO. WHO Handbook for reporting Results of Cancer Treatment. WHO offset publication No.48, Geneva: WHO 1979.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for research and treatment of cancer, National Cancer Institute of the United States, National cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.
16. Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77: 25-79.
17. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-70.
18. Saltz L, Rubin MS, Hochster HS et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer that express epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001; 20:3a. abstract.
19. Saltz LB, Meropol NJ, Loehrer PJ Sr. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
20. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
21. Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology 2001; 15:439-48.
22. Vaccher E, Spina M, Talamini R, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1556-64.